dEEGtal Insight SA, an innovative medical technology startup dedicated to transforming epilepsy diagnostics through AI–powered software, has secured over CHF 1 million in seed funding. This investment, which includes a substantial CHF 750,000 contribution from the Wyss Center in Geneva, will propel dEEGtal’s cutting-edge solution towards clinical validation and market readiness..

dEEGtal Insight SA是一家创新的医疗技术初创公司，致力于通过人工智能驱动的软件改造癫痫诊断，已获得100多万瑞士法郎的种子资金。

A Critical Need for Better Diagnosis Tools for 10 Million Patients Annually

每年1000万患者迫切需要更好的诊断工具

Each year, about 10 million people worldwide experience a possible first epileptic seizure, yet up to 80% of initial EEG readings appear normal, delaying accurate diagnoses and worsening patients’ prognosis. Current diagnostic approaches are highly specific but lack sensitivity, contributing to an alarming 70% risk of relapse in untreated patients and serious impact on quality of life, with potential restrictions on their ability to work or drive..

每年，全世界约有1000万人可能发生首次癫痫发作，但高达80%的初始脑电图读数似乎正常，从而延迟了准确的诊断并恶化了患者的预后。目前的诊断方法具有高度特异性，但缺乏敏感性，未经治疗的患者复发风险高达70%，严重影响生活质量，并可能限制其工作或驾驶能力。

“Our mission at dEEGtal is to bridge this gap by using AI to detect subtle, often-overlooked markers of epilepsy,” says Eric Ménétré, CEO and co-founder of dEEGtal.  Margitta Seeck, head of the EEG and Epilepsy Unit at Geneva University Hospital (HUG), co-founder of dEEGtal, adds: “This cutting-edge approach not only enhances diagnostic precision but also offers a transformative tool for clinicians, enabling earlier interventions and ultimately improving patients' quality of life.”.

dEEGtal首席执行官兼联合创始人埃里克·梅内特雷（EricMénétré）表示：“我们在dEEGtal的使命是通过使用人工智能来检测癫痫的微妙且经常被忽视的标志物，从而弥合这一差距。”。dEEGtal联合创始人、日内瓦大学医院脑电图和癫痫科主任Margitta Seeck补充道：“这种前沿方法不仅提高了诊断的准确性，而且为临床医生提供了一种变革性的工具，可以进行早期干预，最终提高患者的生活质量。”

A Unique AI-Driven Approach

一种独特的人工智能驱动方法

What sets dEEGtal apart is its use of artificial intelligence models trained on large EEG datasets. The software generates a comprehensive risk score even when standard visual indicators of epilepsy are absent, giving doctors vital insights that were previously unattainable. Additionally, dEEGtal offers a user-friendly interface, automated medical reporting, and seamless integration into existing clinical workflows..

使dEEGtal与众不同的是它使用了在大型EEG数据集上训练的人工智能模型。即使没有癫痫的标准视觉指标，该软件也会产生综合风险评分，为医生提供以前无法获得的重要见解。此外，dEEGtal提供了一个用户友好的界面，自动化的医疗报告，以及与现有临床工作流程的无缝集成。。

The CHF 1 million seed round, with CHF 750,000 contributed by the Wyss Center, will be used to refine the AI models, conduct clinical validation studies, and guide dEEGtal to regulation. “We are thrilled to have the Wyss Center’s support. Their expertise in MedTech innovation and regulatory pathways is invaluable as we advance our technology”, Eric Ménétré added..

由Wyss中心出资750000瑞士法郎的100万瑞士法郎种子轮将用于完善AI模型，进行临床验证研究，并指导dEEGtal进行监管。Eric Ménétré补充道：“我们很高兴得到Wyss中心的支持。他们在医疗技术创新和监管途径方面的专业知识在我们推进技术的过程中是非常宝贵的。”

Accelerating Development and Market Entry

加快发展和市场进入

The funding will fast-track dEEGtal’s plans to obtain FDA clearance for the American market, followed by efforts to secure CE marking in Europe and Switzerland. “Our strategy includes introducing our solution in leading neurology centers in the USA and expanding internationally,” explains Stefano Gallotto, CTO and co-founder..

这笔资金将加快dEEGtal在美国市场获得FDA许可的计划，随后将努力在欧洲和瑞士获得CE标志。首席技术官兼联合创始人斯特凡诺·加洛托（StefanoGallotto）解释说：“我们的战略包括将我们的解决方案引入美国领先的神经病学中心，并在国际上进行扩展。”

Targeting a Multi-Billion Dollar Opportunity

瞄准数十亿美元的机会

The global epilepsy diagnostics market is expected to grow from CHF 3.3 billion in 2024 to more than CHF 10 billion by 2032. dEEGtal is well-positioned to capture a substantial share of this market by offering an innovative solution which not only improves diagnostic accuracy but also serves as a tool for ruling out other conditions like syncope and stroke..

全球癫痫诊断市场预计将从2024年的33亿瑞士法郎增长到2032年的100多亿瑞士法郎。dEEGtal通过提供创新解决方案，不仅可以提高诊断准确性，还可以作为排除晕厥和中风等其他疾病的工具，从而占据该市场的巨大份额。

“Epilepsy is just our starting point, but our vision extends way beyond, already foreseeing this technology applied to different neurological diseases” says Stefano Gallotto.(Press release)

斯特凡诺·加洛托（StefanoGallotto）说：“癫痫病只是我们的起点，但我们的视野远远超出了这一点，已经预见到这项技术将应用于不同的神经系统疾病。”（新闻稿）